Alector Inc. Stock News

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa

Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some

Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive

The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in

Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.

The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positiv

Alector (ALEC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to earnings of $0.12 per share a year ago.

Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT

Artificial intelligence technology is transforming many industries and creating new opportunities for businesses and consumers. But as an investor, how can you benefit from this powerful technology?

SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partic

The consensus price target hints at an 86.4% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate